A phase II trial, feasibility of combination of daily cisplatinum and accelerated radiotherapy via concomitant boost in stage III non-small cell lung cancer

Lung Cancer

Volumn 20, Issue 1, 1998, Pages 37-46

  Sarihan, Süreyya ^a   Darendeliler, Emin ^b   Kizir, Ahmet ^b   Tuncel, Nina ^c   Oral, Ethem Nezih ^b   Karadeniz, Ahmet ^b   Bilge, Nijad ^b  

^a ULUDAG UNIVERSITY   (Turkey)

^b Oncology Institute   (Turkey)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Cisplatinum; Concomitant boost; Non small cell lung cancer; Radiosensitizer

Indexed keywords

CISPLATIN; RADIOSENSITIZING AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DOSE FRACTIONATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; SURVIVAL ANALYSIS;

EID: 0031718511     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(98)00003-8     Document Type: Article

References (44)

1. Byhardt RW The evoluation of Radiation Therapy Oncology Group (RTOG) protocols for non-small cell lung cancer. Byrhardt RW, editor. Int J Radiat Oncol Biol Phys. 34:1995;1513-1525.
2. Soresi E, Clerici M, Grilli R et al. A randomized clinical trial comparing radiation therapy and radiation therapy plus cis-dichlorodiammineplatinum (II) in the treatment of locally advanced non-small cell lung cancer. Semin Oncol. 15(S7):1988;20-25.
3. Yu E, Souhami L, Guerro J et al. Accelerated fractionation in inoperable non-small cell lung cancer. Cancer. 71:1993;2727-2731.
4. Emami B, Perez CA Lung. Perez CA, Brady LW Principles and Practice of Radiation Oncology. 1992;806-836 J.B. Lippincott, Philadelphia.
5. Koukourakis M, Skarlatos J, Kosma N et al. Radiotherapy alone for non-small cell lung carcinoma. Acta Oncol. 34:1995;525-530.
6. Blanke CD, Johnson DH Combined modality therapy in non-small cell lung cancer. Curr Opin Oncol. 7:1995;144-149.
7. 4) non-oat cell lung cancer with high dose radiotherapy (rapid fractionation): Radiation Therapy Oncology Group study. Int J Radiat Oncol Biol Phys. 15:1988;1021-1025.
8. 4) non-oat cell lung cancer with concomitant boost radiotherapy by The Radiation Therapy Oncology Group (RTOG 83-12): Long term results. Int J Radiat Oncol Biol Phys. 31:1995;819-825.
9. Byhardt RW, Pajak TF, Emami B et al. A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno and large cell carcinoma of the lung: Report of Radiation Therapy Oncology Group 84-07. Int J Radiat Oncol Biol Phys. 26:1993;459-468.
10. Dosoretz DE, Katin MJ, Blitzer PH et al. Radiation therapy in the management of medically inoperable carcinoma of the lung: Results and implications for future treatment strategies. Int J Radiat Oncol Biol Phys. 24:1992;3-9.
11. Schaake-Koning C, Van Den Bogaert W, Dalesio O et al. Effects of concomitant cisplatinum and radiotherapy on inoperable non-small cell lung cancer. New Engl J Med. 326:1992;524-530.
12. Perez CA, Bauer M, Edelstein S et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys. 12:1986;539-547.
13. Lochrin CA, Wilson GD, McNally NJ et al. Tumor cell kinetics, local tumor control and accelerated radiotherapy: a preliminary report. Int J Radiat Oncol Biol Phys. 24:1992;87-91.
14. Withers HR, Taylor MG, Maciejewski B The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 27:1988;131-146.
15. Arriagada R, Le Chevalier T. Combined modality treatment of locally advanced lung cancer. In: Tobias JS, Thomas PRM, editors. Current Radiation Oncology, 1994:203-230.
16. Cox JD, Pajak TF, Asbell S et al. Interruptions of high dose radiation therapy decrease long-term survival of favorable patientswith unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 RTOG trials. Int J Radiat Oncol Biol Phys. 27:1993;493-498.
17. Fowler JF The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 62:1989;740.
18. Saunders MI, Dische S, Hong A et al. Continuous hyperfractionated accelerated radiotherapy in locally advanced carcinoma of the head and neck region. Int J Radiat Oncol Biol Phys. 17:1989;1287-1293.
19. Saunders MI, Dische S, Grosch EJ et al. Experience with CHART. Int J Radiat Oncol Biol Phys. 21:1991;871-878.
20. Fowler JF. Fractionation and therapeuatic gain. In: Steel GG, Adams GE, Horwich A, editors. The Biological Basis of Radiotherapy, 2nd ed. Amsterdam: Elsevier, 1989:181-207.
21. Horiot JC, Le Fur R, N'Guyen T et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 25(4):1992;231-241.
22. Meoz PT, Fletcher GH, Peters LJ et al. Twice daily fractionation schemes for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 10:1984;831-836.
23. Dillman RO, Seagren SL, Propert KJ et al. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small cell lung cancer. New Engl J Med. 323:1990;940-945.
24. Trovo MG, Minatel E, Veronesi A et al. Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma: a randomized study. Cancer. 65:1990;400-404.
25. Beard CJ, Coleman CN, Kinsella TJ Radiation Sensitizers. DeVita VT, Hellman S, Rosenberg SA Cancer, Principles and Practice of Oncology. 1993;2701-2712 J.B. Lippincott, Philadelphia.
26. Rotman M, Aziz H Continuous infusion chemotherapy and irradiation. Perez CA, Brady LW Principles and Practice of Radiation Oncology. 1992;470-478 J.B. Lippincott, Philadelphia.
27. Dawson-Saunders B, Tropp RG Methods for Analyzing Survival Data. Dawson-Saunders B, Tropp RG Basic and Clinical Biostatistics. 1994;188-209 Appleton and Lange.
28. Chougule PB, Suk S, Chu QD et al. Cisplatinum as a radiation sensitizer in the treatment of advanced head and neck cancers. Cancer. 74:1994;1927-1932.
29. Forastiere AA Concurrent cisplatinum and radiation for advanced head and neck cancer. Forastiere AA, editor. Int J Radiat Oncol Biol Phys. 31:1995;679-680.
30. Dische S Radiotherapy-new fractionation schemes. Semin Oncol. 21(3):1994;304-310.
31. Peters LJ, Ang KK, Thames HD Altered fractionation schedules. Perez CA, Brady LW Principles and Practice of Radiation Oncology. 1992;97-113 J.B. Lippincott, Philadelphia.
32. Cox JD, Azarnia N, Byhardt RW et al. N2 (clinical) non-small cell carcinoma of the lung: Prospective trials of radiation therapy with total dose 60 Gy by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 20:1991;7-12.
33. Oral EN, Aldemir O, Bilge N A pilot study CHART versus conventional radiotherapy in locally advanced non-small cell lung cancer (25 patients). Radiother Oncol. 24:1992;17(abstract).
34. Shimm DR, Cassady JR The skin. Cox JD Moss Radiation Oncology, Rationale, Technique, Results. 7th ed. 1994;99-120 Mosby, St Louis.
35. Douple EB, Eaton WL, Tulloh ME Skin radiosensitization studies using combined cis-dichlorodiammineplatinum(II) and radiation. Int J Radiat Oncol Biol Phys. 5:1979;1383-1385.
36. Knee R, Fields RS, Peters LJ Concomitant boost radiotherapy in head and neck cancer. Arch Otolaryngol. 111:1985;220-222.
37. Simpson JR, Bauer M, Perez CA et al. Radiation therapy alone or combined with Misonidazole in the treatment of locally advanced non-oat cell lung cancer: Report of RTOG prospective randomized trial. Int J Radiat Oncol Biol Phys. 16:1989;1483-1491.
38. Trovo MG, Minatel E, Franchin G et al. Radiotherapy versus radiotherapy enhance by cisplatinum in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 24:1992;11-15.
39. Schuster-Uitterhoeve ALJ, Van de Vaart PJM, Schaake-Koning CCE et al. Feasibility of escalating daily doses of cisplatinum in combination with accelerated radiotherapy in non-small cell lung cancer. Eur J Cancer. 32A(8):1996;1314-1319.
40. Pisch J, Berson AB, Malamed S et al. Chemoradiation in advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 33:1995;183-188.
41. Tejedor M, Valerdi JJ, Lopez V et al. Mitomycin, cisplatinum and vindesine followed by radiotherapy combined with cisplatinum in stage III non-small cell lung cancer: long-term results. Int J Radiat Oncol Biol Phys. 31:1995;813-818.
42. Saunders MI. Accelerated fractionation and its application in clinical radiotherapy. In: Tobias JS, Thomas PRM, editors. Current Radiation Oncology, Edward Arnold, 1994:160-181.
43. Hall EJ Time, dose and fractionation in radiotherapy. Hall EJ Radiobiology for the Radiologist. 1988;239-259 J.B. Lippincott, Phildelphia.
44. Trott KR, Kummermehr K What is known about tumor proliferation rates to choose between accelerated fraction or hyperfraction? Radiother Oncol. 3:1984;1-10.